申请人:KISSEI PHARMACEUTICAL CO., LTD.
公开号:US10011568B2
公开(公告)日:2018-07-03
A problem of the present invention is to provide a new compound which has NK1 receptor antagonist activity, whose CYP3A4 inhibitory activity is reduced compared to aprepitant, and which are useful for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting. That is, the present invention relates to cyclohexyl pyridine derivatives represented by the following formula (I) or a pharmaceutically acceptable salt thereof, wherein, ring A is 4-fluoro-2-methylphenyl or the like; X is a hydrogen atom or the like; R1 is carboxymethyl or the like; R2 is alkyl or the like; Y is 0-2 or the like; U is —N(CH3)COC(CH3)2-3,5-bistrifluoromethylphenyl or the like.
本发明的一个问题是提供一种新化合物,该化合物具有NK1受体拮抗剂活性,其CYP3A4抑制活性与阿瑞匹坦相比有所降低,可用于预防或治疗癌症化疗引起的恶心和呕吐。也就是说,本发明涉及下式(I)所代表的环己基吡啶衍生物或其药学上可接受的盐,其中,环 A 是 4-氟-2-甲基苯基或类似物;X 是氢原子或类似物;R1 是羧甲基或类似物;R2 是烷基或类似物;Y 是 0-2 或类似物;U 是 -N(CH3)COC(CH3)2-3,5-双三氟甲基苯基或类似物。